Skip to main content

Advertisement

Table 2 Parasitological and clinical outcomes among patients treated for uncomplicated P. falciparum malaria with either artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) in 2012–2013 on three sites in Togo

From: Therapeutic efficacy trial of artemisinin-based combination therapy for the treatment of uncomplicated malaria and investigation of mutations in k13 propeller domain in Togo, 2012–2013

Drug Site n Non-PCR-corrected PCR-corrected
Excl/loss ACPR, n (%) LCF LPF TF (%) (95 % CI) Excl/loss ACPR, n (%) LCF LPF TF (%) (95 % CI) Kaplan–Meier AE (%)
ASAQ Lomé 93 0 91 (97.8) 0 2 2 (2.2) (0.3–7.6) 2 91 (100) 0 0 0 (0.0) (0.0–4.0) 0.0 (0.00–0.00) 1 (1.0)
ASAQ Sokodé 86 3 81 (97.6) 1 1 2 (2.4) (0.3–8.4) 5 81 (100) 0 0 0 (0.0) (0.0–4.5) 0.0 (0.00–0.00) 2 (2.3)
ASAQ Niamtougou 83 0 77 (92.8) 0 6 6 (7.2) (2.7–15.1) 3 77 (96.3) 0 3 3 (3.8) (0.8–10.6) 0.03 (0.01–0.10) 1 (1.2)
ASAQ Overall 262 3 249 (96.1) 1 9 10 (3.9) (1.9–7.0) 10 249 (98.8) 0 3 3 (1.2) (0.2–3.4) 1.2 (0. 4–3.6) 4 (1.5)
AL Lomé 90 3 83 (95.4) 1 3 4 (4.6) (1.3–11.4) 7 83 (100) 0 0 0 (0.0) (0.0–4.3) 0.00 (0.00–0.00) 0 (0.0)
AL Sokodé 88 6 72 (87.8) 3 7 10 (12.2) (6.0–21.3) 14 72 (97.3) 0 2 2 (2.7) (0.3–9.4) 0.03 (0.01–0.10) 3 (3.4)
AL Niamtougou 83 7 65 (85.5) 1 10 11 (14.5) (7.5–14.5) 16 65 (97.0) 0 2 2 (3.0) (0.4–10.4) 0.03 (0.01–0.10) 4 (4.8)
AL Overall 261 16 220 (89.8) 5 20 25 (10.2) (4.7–6.7) 37 220 (98.2) 0 4 4 (1.8) (0.5–4.5) 1.7 (0.6–4.4) 7 (2.7)
  1. There were no cases of early treatment failure
  2. ACPR adequate clinical and parasitological response, LCF late clinical failure, LPF late parasitological failure, TF treatment failures (TF = LCF + LPF), AE adverse events